Triglyceride Deposit Cardiomyovasculopathy (TGCV): A Patient Guide

Triglyceride Deposit Cardiomyovasculopathy (TGCV) is an ultra-rare metabolic heart condition that affects how your heart cells create and use energy.

What TGCV Is—and Is Not:

• It is not caused by eating too much fat, and it is not diagnosed by standard blood cholesterol tests.
• It is a problem where heart cells cannot break down the fat droplets stored inside them.
• It can coexist with ordinary coronary disease, meaning standard cardiovascular risk factors like high blood pressure still need strict management.

In a healthy heart, stored fat droplets are broken down by specific enzymes to keep the heart pumping. In TGCV, this process is broken. The heart and blood vessel cells lose the ability to break down intracellular long-chain triglycerides, leading to a state of “energy failure” where the heart lacks the fuel it needs. At the same time, the unused fat builds up inside the cells, causing damage to the heart muscle and the walls of the blood vessels ^[1][2].

This dual problem of energy shortage and fat buildup typically shows up in three main ways: heart failure (where the heart becomes too weak to pump blood effectively), diffuse coronary artery disease (where the blood vessels narrow along their entire length rather than in just one or two focal spots), and ventricular arrhythmias (electrical instability).

Because the problem happens deep inside the cells, standard markers are not enough to confirm it. Instead, doctors often use a specialized nuclear medicine scan called BMIPP scintigraphy to measure how quickly the heart processes a fat-mimicking tracer. An abnormally low “washout rate” on this scan is a hallmark sign that the heart’s metabolic engine is struggling, though it must be carefully interpreted alongside your clinical symptoms by a specialist ^[1][3].

There are two primary ways a person develops TGCV:

• Primary TGCV is a genetic form caused by pathogenic mutations in both copies of the PNPLA2 gene, which provides the instructions for the enzyme responsible for breaking down fats. This form often appears earlier in life and can also affect skeletal muscles.
• Idiopathic TGCV occurs when a patient has all the clinical signs and scan results of the disease but no identifiable genetic mutation. Both types result in a similar inability of the heart to access its intracellular fuel ^[1][4].

Next Steps After Diagnosis

Receiving an accurate diagnosis of a rare disease is the first step toward a specialized management plan.

1. Confirm the Diagnosis: Ensure an experienced center reviews your exact BMIPP and genetic results.
2. Make a Symptom Plan: Know exactly when to call your doctor or emergency services for worsening chest pain or breathlessness.
3. Continue Care: Do not stop your ordinary heart failure or coronary medications unless your clinician explicitly changes them.

While there is no simple cure, your care team can use a combination of individualized heart failure medications, advanced monitoring, and careful assessment of your blood vessels. Investigational treatments like tricaprin (CNT-01) are also being studied in clinical trials to see if providing an alternative metabolic energy source can safely help ^[1][5]. By working with a multidisciplinary team, you can focus on protecting your heart’s function and maintaining your quality of life.